BCR-ABL mutation-guided therapy for CML blast crisis: A case report

2Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of dif-ferent treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.

Cite

CITATION STYLE

APA

Ostendorf, B. N., Nogai, H., Baldus, C. D., Burmeister, T., & Arnold, R. (2015). BCR-ABL mutation-guided therapy for CML blast crisis: A case report. Biomarker Insights, 10, 25–28. https://doi.org/10.4137/Bmi.s22279

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free